Peginesatide

Drug Levels and Effects:




Summary of Use during Lactation:


No information is available on the clinical use of peginesatide during breastfeeding. Because of its large molecular weight of 4900 daltons, excretion into breastmilk should be minimal and it would not be expected to be absorbed from breastmilk by the infant. If peginesatide is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.


Drug Levels:


Maternal Levels.

Relevant published information was not found as of the revision date.

Infant Levels.

Relevant published information was not found as of the revision date.


Effects in Breastfed Infants:


Relevant published information was not found as of the revision date.


Possible Effects on Lactation:


Relevant published information was not found as of the revision date.


Alternate Drugs to Consider:


Epoetin Alfa


References:






Substance Identification:




Substance Name:

Peginesatide

CAS Registry Number:

913976-27-9

Drug Class:


  • Colony-Stimulating
  • Factors
  • Hematinics

  • Hematopoietic Cell Growth
  • Factors

    Administrative Information:




    LactMed Record Number:


    996


    Last Revision Date:


    Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.